Fungaemia due to rare yeasts in a tertiary care university centre within 18 years

Alp Ş., Gulmez D., Ayaz C., Arikan-Akdagli S., Akova M.

MYCOSES, cilt.63, sa.5, ss.488-493, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Sayı: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1111/myc.13072
  • Dergi Adı: MYCOSES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.488-493
  • Anahtar Kelimeler: amphotericin B, antifungal resistance, antifungal treatment, azoles, breakthrough fungaemia, echinocandins, fungaemia, rare yeast, INFECTIOUS-DISEASES SOCIETY, CLINICAL-PRACTICE GUIDELINE, SAPROCHAETE-CAPITATA, HEMATOLOGICAL MALIGNANCIES, RHODOTORULA-MUCILAGINOSA, CANDIDIASIS, MANAGEMENT, DIAGNOSIS, CANCER, UPDATE
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background Fungaemia due to rare yeasts has been recognised as an emerging, clinically relevant, but less investigated condition. Intrinsic resistance or reduced susceptibility of these species to echinocandins or fluconazole remains as a challenge in empirical treatment.